Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Badesch

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
The New England Journal of Medicine|March 22, 2002
Bosentan therapy for pulmonary arterial hypertensionLewis J Rubin, David B Badesch, Robyn J Barst, et al.
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|February 21, 2015
[Definitions and diagnosis of pulmonary hypertension]Marius M Hoeper, Harm Jan Bogaard, Robin Condliffe, et al.
American Journal of Respiratory and Critical Care Medicine|September 2, 2006
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertensionVallerie V McLaughlin, Ronald J Oudiz, Adaani Frost, et al.
Chest|January 23, 2018
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL RegistryRobert P Frantz, Harrison W Farber, David B Badesch, et al.
Chest|November 10, 2018
ResponseRobert P Frantz, Carol Zhao, Harrison W Farber, et al.
Journal of the American College of Cardiology|December 21, 2013
Definitions and diagnosis of pulmonary hypertensionMarius M Hoeper, Harm Jan Bogaard, Robin Condliffe, et al.
Chest|May 7, 2011
Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 studyLewis J Rubin, David B Badesch, Thomas R Fleming, et al.
Journal of the American College of Cardiology|June 27, 2009
Diagnosis and assessment of pulmonary arterial hypertensionDavid B Badesch, Hunter C Champion, Miguel Angel Gomez Sanchez, et al.
Chest|September 25, 2008
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalitiesMichael D McGoon, Adaani E Frost, Ronald J Oudiz, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 13, 2014
Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertensionGérald Simonneau, Lewis J Rubin, Nazzareno Galiè, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
The New England Journal of Medicine|March 22, 2002
Bosentan therapy for pulmonary arterial hypertensionLewis J Rubin, David B Badesch, Robyn J Barst, et al.
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|February 21, 2015
[Definitions and diagnosis of pulmonary hypertension]Marius M Hoeper, Harm Jan Bogaard, Robin Condliffe, et al.
American Journal of Respiratory and Critical Care Medicine|September 2, 2006
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertensionVallerie V McLaughlin, Ronald J Oudiz, Adaani Frost, et al.
Chest|January 23, 2018
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL RegistryRobert P Frantz, Harrison W Farber, David B Badesch, et al.
Chest|November 10, 2018
ResponseRobert P Frantz, Carol Zhao, Harrison W Farber, et al.
Journal of the American College of Cardiology|December 21, 2013
Definitions and diagnosis of pulmonary hypertensionMarius M Hoeper, Harm Jan Bogaard, Robin Condliffe, et al.
Chest|May 7, 2011
Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 studyLewis J Rubin, David B Badesch, Thomas R Fleming, et al.
Journal of the American College of Cardiology|June 27, 2009
Diagnosis and assessment of pulmonary arterial hypertensionDavid B Badesch, Hunter C Champion, Miguel Angel Gomez Sanchez, et al.
Chest|September 25, 2008
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalitiesMichael D McGoon, Adaani E Frost, Ronald J Oudiz, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 13, 2014
Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertensionGérald Simonneau, Lewis J Rubin, Nazzareno Galiè, et al.
Pageof 9